Roche appreciates 5.8% on promising oral anti-obesity data

NEWS. Roche finished Wednesday 5.8% up, corresponding to more than USD 16 billion in market cap, after disclosing Phase 1 data from CT-996 in obese patients, showing 7.3% weight loss (6.1% placebo-adjusted) after four weeks of treatment. Importantly, there were no treatment discontinuations, and according to the company the compound’s side effect profile is in-line with other similar molecules.

BACKGROUND. Roche entered the obesity field at the end of 2023 by acquiring Carmot Therapeutics for USD 2.7 billion with three clinical drug candidates. One of them, CT-996 is an oral small molecule targeting GLP-1, the same peptide as Novo Nordisk’s semaglutide (brand name: Wegovy, Ozempic).

COMPETITION. Although only limited data was disclosed this time, CT-996 compared favorably to peers. As an oral drug it is thought to be more convenient than injectables and as a small molecule it is easier and cheaper to manufacture than (oral) peptides, which are more complex chemical constructs built from amino acids.

More specifically, CT-996 apparently led to a numerically larger and more rapid weight loss than Viking Therapeutics’ GLP-1/GIP agonist oral peptide (5.3% weight loss in 4 weeks, 3.3% placebo-adjusted). However, Viking’s drug has a clean safety profile, while Roche did not disclose any further details on the side effects of CT-996. Roche’s drug also compares favorably to Eli Lilly’s orfoglipron and Structure Therapeutics’ GSBR-1290, that showed a 6-8% weight loss in 12 weeks. Additionally, competition is expected to intensify among oral small molecules aiming to treat obesity, as other large companies including AstraZeneca, Pfizer and Gilead are also working on similar drugs, not to mention several smaller biotech companies like Terns Pharmaceuticals, that also plan to establish themselves in the field of obesity.

UNCERTAINTIES. While comparing drugs across different clinical trials can be useful, this exercise comes several caveats. We do not know much about dose escalation in Roche’s trial - that is how frequently and to what extent did the company increase the dose during the trial – which varies trial by trial and can substantially affect the results. Additionally, no details on the side effect profile were disclosed, but Roche will present it at a medical conference, which will further clarify the picture.

CONCLUSION. To sum up, this announcement came at a favorable time for Roche. After multiple clinical setbacks in the last couple of years these favorable early results are a step towards restoring investor confidence in the company’s drug development capabilities.

Latest news

  1. Arctic Asset Management -

    Arctic Midt i Måneden - Ny markedsvirkelighet krever selektive valg – og spesialister med global rekkevidde. Velkommen til Arctic Global Select!

    Forvalter Tone Varmann og Anders Engebretsen er i studio med investeringsdirektør Albert Collett der de forteller om det nye, globale aksjefondet Arctic Global Select.

    I en verden der deler av aksjemarkedet er rekordhøyt priset, mens andre segmenter ligger under radaren, spør vi: Hvordan navigerer man som investor i dette landskapet? Svaret, ifølge Varmann og Engebretsen, ligger i å være godt diversifisert men likevel selektiv — og å kunne gå dit markedet ikke ser.

  2. Arctic Asset Management -

    Markedskommentar februar 2025

    Nyhetsbildet i februar ble spesielt preget av sterke utspill fra president Trump der de største temaene med europeiske øyne har vært om handelspolitikk og krigen i Ukraina. Konsekvensene av Trumps politikk, med påfølgende 2. og 3. hånds implikasjoner, er vanskelige å spå så det har først og fremst skapt økt usikkerhet, men det er liten tvil om at Trump signaliserer en ‘USA first’ politikk der amerikansk middelklasse skal styrkes gjennom økt innenlands produksjon og bedring i statsfinansene.

  3. Arctic Asset Management -

    Arctic Midt i Måneden - Store utslag og skarpe analyser

    Rapporteringsesong med store kursutslag, en president som har gått høyt ut om toll og tariffer, og en dose krig og fred. Aksjeforvalterne Kay-Erik Mamre-Johansen og Arild Huitfeldt diskuterer de viktigste hendelsene med Albert Collett i en forrykende episode.

  4. Arctic Asset Management -

    Markedskommentar januar 2025

    Innsettelsen av President Trump, forventninger om økte tollsatser i viktige regioner og AI-nyheter preget markedet i januar. Det globale aksjemarkedet hadde en sterk åpning på året med verdensindeksen opp 3,8 % målt ved MSCI World Index (NOK) og fortsatte med det den gode utviklingen fra fjoråret.